Literature DB >> 8046415

Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes.

G F Rimmelzwaan1, K H Siebelink, R C Huisman, B Moss, M J Francis, A D Osterhaus.   

Abstract

Recombinant vaccinia viruses were constructed that expressed the complete env gene of feline immunodeficiency virus with or without the nucleotide sequence encoding the cleavage site between the surface (SU) protein and the transmembrane (TM) protein. The removal of this cleavage site resulted in the expression of a 150K protein that was processed into a 130K protein and was not cleaved into the SU and the TM proteins. Removal of the cleavage site also facilitated incorporation of the SU protein in immune-stimulating complexes (iscoms). Antibody responses to both an SU and a TM peptide representing two immunodominant B cell epitopes were measured. These were higher in cats immunized with iscoms prepared from the cleavage site-deleted envelope protein than in cats immunized with iscoms prepared from the native envelope protein or immunized with the envelope protein and the adjuvant Quil A.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8046415     DOI: 10.1099/0022-1317-75-8-2097

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes.

Authors:  J T Voeten; T M Bestebroer; N J Nieuwkoop; R A Fouchier; A D Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).

Authors:  E G Hulskotte; A M Geretti; K H Siebelink; G van Amerongen; M P Cranage; E W Rud; S G Norley; P de Vries; A D Osterhaus
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

3.  A mutation in the HLA-B*2705-restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro.

Authors:  E G M Berkhoff; A C M Boon; N J Nieuwkoop; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  Functional compensation of a detrimental amino acid substitution in a cytotoxic-T-lymphocyte epitope of influenza a viruses by comutations.

Authors:  G F Rimmelzwaan; E G M Berkhoff; N J Nieuwkoop; R A M Fouchier; A D M E Osterhaus
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

5.  Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.

Authors:  K H Siebelink; E Tijhaar; R C Huisman; W Huisman; A de Ronde; I H Darby; M J Francis; G F Rimmelzwaan; A D Osterhaus
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

Review 6.  Vaccine delivery using nanoparticles.

Authors:  Anthony E Gregory; Richard Titball; Diane Williamson
Journal:  Front Cell Infect Microbiol       Date:  2013-03-25       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.